AAAAAA

   
Results: 1-17 |
Results: 17
In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity
Authors: Smith, PG Thomas, HD Barlow, HC Griffin, RJ Golding, BT Calvert, AH Newell, DR Curtin, NJ
Citation: Pg. Smith et al., In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity, CLIN CANC R, 7(7), 2001, pp. 2105-2113
The impact of p53 status on cellular sensitivity to antifolate drugs
Authors: Lu, XH Errington, J Curtin, NJ Lunec, J Newell, DR
Citation: Xh. Lu et al., The impact of p53 status on cellular sensitivity to antifolate drugs, CLIN CANC R, 7(7), 2001, pp. 2114-2123
Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue
Authors: Monks, NR Blakey, DC Curtin, NJ East, SJ Heuze, A Newell, DR
Citation: Nr. Monks et al., Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue, BR J CANC, 85(5), 2001, pp. 764-771
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro
Authors: Bowman, KJ Newell, DR Calvert, AH Curtin, NJ
Citation: Kj. Bowman et al., Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro, BR J CANC, 84(1), 2001, pp. 106-112
Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole
Authors: Marshman, E Taylor, GA Thomas, HD Newell, DR Curtin, NJ
Citation: E. Marshman et al., Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole, BIOCH PHARM, 61(4), 2001, pp. 477-484
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines
Authors: Delaney, CA Wang, LZ Kyle, S White, AW Calvert, AH Curtin, NJ Durkacz, BW Hostomsky, Z Newell, DR
Citation: Ca. Delaney et al., Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines, CLIN CANC R, 6(7), 2000, pp. 2860-2867
Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines
Authors: Lu, XH Errington, J Chen, VJ Curtin, NJ Boddy, AV Newell, DR
Citation: Xh. Lu et al., Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines, CLIN CANC R, 6(1), 2000, pp. 271-277
Resistance-modifying agents. Part 7: 2, 6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presenceof alpha(1)-acid glycoprotein (AGP)
Authors: Barlow, HC Bowman, KJ Curtin, NJ Calvert, AH Golding, BT Huang, B Loughlin, PJ Newell, DR Smith, PG Griffin, RJ
Citation: Hc. Barlow et al., Resistance-modifying agents. Part 7: 2, 6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presenceof alpha(1)-acid glycoprotein (AGP), BIOORG MED, 10(6), 2000, pp. 585-589
Resistance-modifying agents. 8. Inhibition of O-6-alkylguanine-DNA alkyltransferase by O-6-alkenyl-, O-6-cycloalkenyl-, and O-6-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O-6-(1-cyclopentenylmethyl)guanine
Authors: Griffin, RJ Arris, CE Bleasdale, C Boyle, FT Calvert, AH Curtin, NJ Dalby, C Kanugula, S Lembicz, NK Newell, DR Pegg, AE Golding, BT
Citation: Rj. Griffin et al., Resistance-modifying agents. 8. Inhibition of O-6-alkylguanine-DNA alkyltransferase by O-6-alkenyl-, O-6-cycloalkenyl-, and O-6-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O-6-(1-cyclopentenylmethyl)guanine, J MED CHEM, 43(22), 2000, pp. 4071-4083
Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase
Authors: White, AW Almassy, R Calvert, AH Curtin, NJ Griffin, RJ Hostomsky, Z Maegley, K Newell, DR Srinivasan, S Golding, BT
Citation: Aw. White et al., Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase, J MED CHEM, 43(22), 2000, pp. 4084-4097
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
Authors: Arris, CE Boyle, FT Calvert, AH Curtin, NJ Endicott, JA Garman, EF Gibson, AE Golding, BT Grant, S Griffin, RJ Jewsbury, P Johnson, LN Lawrie, AM Newell, DR Noble, MEM Sausville, EA Schultz, R Yu, W
Citation: Ce. Arris et al., Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles, J MED CHEM, 43(15), 2000, pp. 2797-2804
Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)
Authors: Monks, NR Calvete, JA Curtin, NJ Blakey, DC East, SJ Newell, DR
Citation: Nr. Monks et al., Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT), BR J CANC, 83(2), 2000, pp. 267-269
Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport
Authors: Smith, PG Marshman, E Newell, DR Curtin, NJ
Citation: Pg. Smith et al., Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport, BR J CANC, 82(4), 2000, pp. 924-930
Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro
Authors: Curtin, NJ Turner, DP
Citation: Nj. Curtin et Dp. Turner, Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro, EUR J CANC, 35(6), 1999, pp. 1020-1026
Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growthinhibition by dipyridamole in human lung cancer cell lines
Authors: Smith, PG Marshman, E Calvert, AH Newell, DR Curtin, NJ
Citation: Pg. Smith et al., Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growthinhibition by dipyridamole in human lung cancer cell lines, SEMIN ONCOL, 26(2), 1999, pp. 63-67
Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha(1)-acid glycoprotein binding
Authors: Curtin, NJ Bowman, KJ Turner, RN Huang, B Loughlin, PJ Calvert, AH Golding, BT Griffin, RJ Newell, DR
Citation: Nj. Curtin et al., Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha(1)-acid glycoprotein binding, BR J CANC, 80(11), 1999, pp. 1738-1746
Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)
Authors: Griffin, RJ Srinivasan, S Bowman, K Calvert, AH Curtin, NJ Newell, DR Pemberton, LC Golding, BT
Citation: Rj. Griffin et al., Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), J MED CHEM, 41(26), 1998, pp. 5247-5256
Risultati: 1-17 |